Close Menu

NEW YORK (GenomeWeb) — iCubate said today that it has formed a joint venture with Wondfo Biotech to commercialize infectious disease molecular diagnostics in China.

The joint venture — called Wondfo-iCubate Biotech — will develop assays using iCubate's amplicon-rescued multiplex PCR (arm-PCR) technology, which the company has said can amplify up to a quarter of a million unique targets in one reaction with high specificity and sensitivity. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.